Published in Cardiovasc Drugs Ther on January 01, 1993
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Complications of diuretic therapy in hepatic cirrhosis. Lancet (1966) 2.09
Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med (1970) 1.58
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology (1983) 1.33
Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol (1986) 1.05
Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung (1988) 1.04
Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol (1986) 0.99
Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med (1979) 0.97
Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung (1988) 0.95
Relation of acute potassium depletion to renal ammonium metabolism in patients with cirrhosis. J Clin Invest (1963) 0.93
Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther (1987) 0.93
Furosemide disposition in cirrhotic patients. Gastroenterology (1981) 0.90
Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther (1986) 0.87
Torasemide for diuretic treatment of advanced chronic renal failure. Arzneimittelforschung (1988) 0.87
Single dose comparison of torasemide and furosemide in patients with advanced renal failure. Arzneimittelforschung (1988) 0.86
Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung (1988) 0.86
Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J (1975) 0.85
Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers. Eur J Clin Pharmacol (1986) 0.83
Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology (1987) 0.80
Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittelforschung (1988) 0.80
Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Am J Dig Dis (1978) 0.79
The rational management of ascites. Prog Liver Dis (1972) 0.78
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (1996) 4.54
Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol (1992) 3.35
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol (1999) 2.70
Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis (2001) 2.35
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia (2008) 2.32
Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology (1997) 2.16
Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology (2000) 2.09
Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology (1999) 2.07
Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis (2003) 2.06
Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol (1998) 2.01
Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol (1996) 1.68
Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem (2001) 1.61
ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest (2007) 1.59
HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest (1998) 1.59
Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis (2011) 1.58
Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. Gastroenterology (1993) 1.55
Signal transduction in hepatic stellate cells. Liver (1998) 1.55
Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology (1996) 1.52
Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology (1993) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut (2008) 1.43
Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology (1999) 1.41
Effects of exercise on natriuretic peptides and cardiac function in man. Int J Cardiol (1998) 1.39
Prevention of work related eye injuries: long term assessment of the effectiveness of a multicomponent intervention among metal workers. Occup Environ Med (2005) 1.38
Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J Biol Chem (1999) 1.30
Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol (2000) 1.29
Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology (1997) 1.27
Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol (1996) 1.24
Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology (1998) 1.22
Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sex Transm Infect (2008) 1.21
Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology (2000) 1.15
Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut (2005) 1.13
Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology (2000) 1.13
Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology (1992) 1.09
Transforming growth factor-beta 1 regulates platelet-derived growth factor receptor beta subunit in human liver fat-storing cells. Hepatology (1995) 1.08
T(14;18) translocation in chronic hepatitis C virus infection. Hepatology (2000) 1.08
The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology (2001) 1.06
Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med (1999) 1.04
Prostaglandins, thromboxanes and leukotrienes in clinical medicine. West J Med (1985) 1.02
Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med (1999) 1.02
Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem (2000) 1.01
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (2000) 1.01
Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol (1999) 1.01
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology (1997) 1.00
Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase. FASEB J (2001) 0.98
Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab (2000) 0.98
Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol (1995) 0.97
Endothelin-1 induces serine phosphorylation of the adaptor protein p66Shc and its association with 14-3-3 protein in glomerular mesangial cells. J Biol Chem (2001) 0.97
Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol (1997) 0.96
Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension (1998) 0.95
Focal adhesion kinase and phospholipase C gamma involvement in adhesion and migration of human hepatic stellate cells. Gastroenterology (1997) 0.95
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology (2001) 0.95
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat (2006) 0.95
c-Src activates both STAT1 and STAT3 in PDGF-stimulated NIH3T3 cells. Biochem Biophys Res Commun (1997) 0.95
Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology (1997) 0.94
Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. FEBS Lett (1995) 0.94
Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol (1997) 0.92
Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology (1996) 0.92
Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol (1999) 0.92
Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology (1992) 0.91
Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol (2000) 0.91
Chlamydia trachomatis in adolescents and adults. Clinical and economic implications. Pharmacoeconomics (1998) 0.90
The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling. J Biol Chem (1998) 0.90
LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Biochem Biophys Res Commun (1997) 0.89
Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem (2000) 0.89